ライフサイエンスコーパス: liver function test

1 s (all liver transplant patients with normal liver function tests).

2 ts to withdraw steroid resulted in a rise in liver function test.

3 ts were assessed by pure tone audiometry and liver function tests.

4 up to 109/mL) lasting 5--6 days and abnormal liver function tests.

5 Blood was drawn for leukocyte counts and liver function tests.

6 significantly higher in those with abnormal liver function tests.

7 nosis, were well and had normal results from liver function tests.

8 ischemia was determined by survival time and liver function tests.

9 amination to her family doctor with abnormal liver function tests.

10 d graft outcome than any of the conventional liver function tests.

11 ic control, blood pressure, lipid tests, and liver function tests.

12 uence postoperative AST peak values or other liver function tests.

13 difference was found in other postoperative liver function tests.

14 vity of liver disease, which is reflected by liver function tests.

15 te dehydrogenase (LDH), 397 IU/L; and normal liver function tests.

16 Serologic, histologic, and liver function tests.

17 ad jaundice and markedly abnormal results on liver function tests.

18 stasis had abnormal findings on simultaneous liver function tests.

19 e (SARS), many patients had abnormalities in liver function tests.

20 pyrexia, somnolence, and abnormal results on liver-function tests.

21 a, vomiting, fatigue, alopecia, and elevated liver-function tests.

22 , ABO blood group matching, and preoperative liver function testing.

23 diarrhea (35%), anemia (18%), and increased liver function tests (12%).

24 Inclusion criteria were liver function tests 2.5 times the upper limit of normal

25 ting for ECD-liver status included: elevated liver function tests (20%), hypernatremia (12.6%), and e

26 mas (34 [10%]), rash (30 [9%]), and abnormal liver function tests (38 [11%]) in the vemurafenib group

27 bleeding (17/38), ascites (6/38), increased liver function tests (6/38), splenomegaly (5/38), or scr

28 Patients underwent endoscopy, liver biopsy, liver function tests, abdominal ultrasonography, a detai

29 two patients at that dose level) and grade 4 liver function test abnormalities (in one patient).

30 olated Ductular Hyperplasia in patients with liver function test abnormalities and other topics with

31 Liver function test abnormalities are common in patients

32 uate the frequency, pattern, and severity of liver function test abnormalities in patients with Lyme

33 Neutropenia, peripheral edema, and liver function test abnormalities were dose-limiting at

34 viduals with no other identifiable cause for liver function test abnormalities who presented with EM

35 the percentage of patients with any abnormal liver function test after baseline sampling was similar

36 as determined by body mass index (BMI), and liver function tests (ALT, AST, and GGT) in a random sam

37 ALT) (27%) were the most frequently elevated liver function tests among Lyme disease patients.

38 The liver function test and histological study revealed mini

39 Renal and liver function tests and biopsies revealed a lack of nep

40 erative [POD] day 21) was proven by elevated liver function tests and biopsy.

41 Monitoring was by liver function tests and coagulation parameters.

42 Liver function tests and histology revealed only minor p

43 Liver function tests and synthetic function were monitor

44 ll tolerated, with only modest elevations of liver function tests and thrombocytopenia, each being ob

45 re cohort, these miRNAs were correlated with liver function tests and were independent predictors of

46 mptoms-which include fever, anemia, elevated liver function tests, and hemoglobinuria-may be especial

47 g on CsA, whereas thrombocytopenia, abnormal liver function tests, and hypokalemia were reported more

48 aspofungin) local phlebitis, fever, abnormal liver function tests, and mild haemolysis.

49 acteristics, including pretreatment history, liver function tests, and PET/CT parameters, were assess

50 NA, HCV genotype (nucleic acid tests [NAT]), liver function tests, and platelet counts; patient age w

51 ase score, pre- and post-DIPS PSGs, pre-DIPS liver function tests, and pre-DIPS creatinine levels.

52 ic, pancreatitis, unexplained derangement of liver function tests, and/or dilated CBD without an iden

53 A full blood count; liver function test; and measurements of urea and electr

54 Asymptomatic patients with abnormal liver function tests are common in the lipid clinic, and

55 Although the liver function tests are elevated in an organ donor, the

56 Chest x-rays, CBCs, and liver function tests are not recommended, and molecular

57 We further discuss the use of liver function tests as prognostic markers in patients w

58 y seems to be the most valuable quantitative liver function test, as it can measure multiple aspects

59 No grade >1 alterations in liver function tests associated with CV706 administratio

60 A uniform policy of liver function testing at 2 weeks is useful for prompt i

61 recorded indications for ultrasonography and liver function tests at diagnosis, management of HAT, an

62 Of these women 49% had normal liver function tests at the time of survey, 33% mildly a

63 patients with liver dysfunction [>/= grade 2 liver function tests] at greater risk).

64 animal survival, hepatic tissue blood flow, liver function tests, blood and tissue biochemistry, and

65 d a rash and another had elevated results on liver-function tests; both of these effects resolved wit

66 of a common duct stone (including increased liver function tests but bilirubin <4 mg/dL and no chola

67 ucose to the rat donors affected outcome and liver functions tested by isolated perfusion after 24- a

68 w-up data consisted of physical examination, liver function tests, CEA, chest X-ray, computed tomogra

69 require rethinking our definition of "normal liver function tests." Chronic viral hepatitis B and C r

70 monitoring, including toxicology screening, liver function tests, coagulation studies, serum chemist

71 For individuals with abnormal liver function tests, common causes of hepatitis, includ

72 ur more frequently in patients with elevated liver function tests compared with those with normal val

73 ass index (BMI), HBV DNA level, HBsAg level, liver function test, complete blood count, aspartate ami

74 Liver function tests decreased from baseline to end of t

75 tly greater (P < 0.05) incidence of abnormal liver function tests, diarrhea, hypokalemia, and thrombo

76 platelet count, serum creatinine level, and liver function tests did not change significantly from b

77 However, traditional liver function tests do not provide quantitative data ab

78 Seven patients experienced a rise in liver function tests during the period of increased ster

79 Grade 3/4 toxicities included liver function test elevation (14%), pneumonitis (9%), d

80 nts were nausea, edema, confusion, diarrhea, liver function test elevation, fatigue, and myalgia.

81 ade 3 to 4 toxicities consisted primarily of liver function test elevations (24%), nausea/vomiting (1

82 sical examination, complete blood count, and liver function tests every 3 months and a chest radiogra

83 Adverse events included abnormalities in liver-function tests, fatigue, nausea, headache, dizzine

84 Unit (ICU) and hospital stay, postoperative liver function tests, fatty acid and eicosanoid concentr

85 serum erythrocyte protoporphyrin levels and liver function tests following treatment were assessed.

86 of intraoperative biopsies and postoperative liver function tests for the development of preservation

87 NE search was performed using the key words "liver function tests," "functional studies in the liver,

88 sistance, serum ferritin, lipid profile, and liver function tests improved irrespective of bloodletti

89 After antibiotic treatment, elevated liver function tests improved or resolved in most patien

90 ept for apparently reversible alterations in liver function tests in approximately 6% of subjects, al

91 Elevated liver function tests in CFTR-knockout kits were correcte

92 Morphologic studies at necropsy and liver function tests in dogs receiving hemoglobin soluti

93 The results of liver function tests in the naltrexone group were simila

94 ied secondary outcomes, including adiposity, liver function tests, incidence of conjugated hyperbilir

95 al blood counts, electrolytes, and renal and liver function tests (including lactic acid dehydrogenas

96 Passive liver function tests, including biochemical parameters a

97 Postoperative liver function tests, intensive care unit stay, hospital

98 h reversible, elevated liver enzymes; hence, liver function testing is needed to identify those unsui

99 Treatment records including liver function test (LFT) results at baseline and during

100 Five (15%) patients had liver function test (LFT) results that were more than ei

101 Although liver function tests (LFTs) are routinely measured in pr

102 each case, a point of acute deterioration in liver function tests (LFTs) was identified ("start time"

103 ociated with elevated liver enzyme levels on liver function tests (LFTs), and there were higher conce

104 able disease measures, including skin score, liver function tests (LFTs), blood counts, and lung func

105 ther symptom-based screening, screening with liver function tests (LFTs), HCV antibody (Ab) screening

106 om a brain-death donor was declined for high liver function tests (LFTs).

107 (IBD) are frequently associated with altered liver function tests (LFTs).

108 l were on tacrolimus monotherapy with normal liver function tests (LFTs).

109 the extent of IRI were assessed by measuring liver function tests, lipid peroxidation, and metallopro

110 no or minimal hepatic injury who had normal liver function tests (LTs) (referred to herein as the no

111 was systemic, manifested as an elevation in liver function tests, malaise, and edema.

112 Elevations in liver function tests (more than three times normal), all

113 the suitability for transplantation included liver function tests, morphologic and histologic assessm

114 burden of >900 mg/kg, marked improvement in liver function tests, much less neurodegeneration, and,

115 presenting with ascites (n = 10), increased liver function tests (n = 2), and splenomegaly (n = 2).

116 cholangiography, liver biopsy, and/or serial liver function tests (n = 38).

117 (N = 373) of 709 patients based on abnormal liver function tests, neutropenia, history of IV drug us

118 Liver function tests, nitrite + nitrate (NOx) and plasma

119 luzole was well tolerated; mean increases in liver function tests occurred but drug discontinuation w

120 Only mild and transient elevation of liver function tests occurred in 4 of 15 dogs.

121 , weight, liver size, blood lipids and blood liver function tests of the subjects were measured.

122 in patients with prolonged abnormalities of liver function tests of uncertain origin.

123 ostoperative complications, or perioperative liver function tests on liver regeneration.

124 e patient has subsequently maintained normal liver function tests on low-dose prednisone alone, with

125 ho are taking statins, routine monitoring of liver function tests or muscle enzymes is not recommende

126 (SNPs) near 7 loci have been associated with liver function tests or with liver steatosis by magnetic

127 is (stage >or= 3), with histologic analysis, liver function tests, or MR imaging as the reference sta

128 ) developed symptoms of PBC and 24 (83%) had liver function tests persistently showing cholestasis.

129 hanges in blood chemistry (glucose, lactate, liver function tests, prothrombin time) and to assess li

130 We measured disease severity by quantitative liver function tests (QLFTs) to determine cutoffs for QL

131 latelet counts, serum creatinine values, and liver function tests remained normal in all animals rece

132 eatment, all patients had improved or normal liver function tests, resolution of C4d deposition and s

133 Symptoms were: elevated liver function test results (serum glutamic oxaloacetic

134 biliary cirrhosis (PBC), but who had normal liver function test results and no symptoms of liver dis

135 tion of serum aminotransferase levels; other liver function test results are usually normal.

136 of symptoms, body mass index, calcium level, liver function test results before and at symptom onset,

137 Three volunteers had abnormal liver function test results temporally associated with i

138 Clinical evaluation and assessment of liver function test results were done daily during hospi

139 Thyroid and liver function test results were normal, but she had rap

140 er, white blood cell count, bilirubin level, liver function test results) was conducted by reviewing

141 anorexia, constipation, dizziness, elevated liver function test results, fever, headache, heartburn,

142 ated with patient survival, acute rejection, liver function test results, recurrence of viral or othe

143 cose, and lipid levels, insulin sensitivity, liver function test results, waist circumference, blood

144 p discontinued the study because of elevated liver function test results.

145 s investigated for liver disease or abnormal liver function test results.

146 Liver injury ranged from abnormal liver-function test results to rapidly progressive and f

147 Histology studies and liver function tests reveal that no apparent toxicity is

148 Postoperative liver function testing revealed significant early differ

149 Liver function tests revealed severe hepatocellular inju

150 y periodic surveillance with hepatic USG and liver function tests scheduled every 6 months for the fi

151 Liver function tests, serum electrolytes, and cholestero

152 Neutropenia, elevated liver-function tests, serum creatinine elevations and li

153 Patients with XHIM who have abnormal liver function tests should be considered at increased r

154 computed tomography volumetry, quantitative liver function tests should be used to determine whether

155 Liver function tests showed higher levels of aspartate a

156 rmal baseline liver function (n = 49 [47%]), liver function tests significantly improved from baselin

157 All seven patients had normal liver function tests, skin rash, and diagnosis of GvHD h

158 Dynamic quantitative liver function tests, such as the indocyanine green test

159 dity score, and medications that can elevate liver function tests sufficiently to necessitate discont

160 ing EVG/COBI/FTC/TDF had abnormal results in liver function tests than did those receiving ATV/RTV+FT

161 Four (14.2%) had modest elevations in liver function tests (two biopsy proven mild rejections

162 iver volumes, radiation doses, and serologic liver function tests (unpaired t test, P = 0.05) and 2)

163 ow in the HM was lower than in controls, and liver function tests were abnormal.

164 Liver function tests were assessed monthly.

165 ences of PHP and stroma-free hemoglobin with liver function tests were determined and recommendations

166 egorized with NAFLD Activity Score (NAS) and liver function tests were done before surgery and after

167 iate for paclitaxel therapy who had abnormal liver function tests were eligible.

168 mphocytes, monocytes, platelets, D-dimer and liver function tests were observed 24 to 48 hours after

169 cant changes in triacylglycerol, glucose, or liver function tests were observed with Sterol Bev.

170 om mutant and control mice were examined and liver function tests were performed.

171 Liver function tests were performed.

172 Liver function tests were repeated after portal pumping.

173 At EOP, liver function tests were similar but creatinine clearan

174 n site reactions and transient elevations of liver function tests were the most notable side effects.

175 Liver histology and liver function tests were unaffected in transgenic anima

176 tes of infection, rash, and abnormalities on liver-function testing were higher with daclizumab HYP t

177 -related adverse events and abnormalities on liver-function testing were more common with abiraterone

178 mple values (for chemistry, hematologic, and liver function tests) were checked at regular intervals

179 Reliance on abnormal liver function tests will miss most patients with signif

180 Normalization of liver function tests with improvement in viremia was ach